CHEST 2026: Day 2 Recap — 4 Headlines to Know - HCPLive
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
News|Articles|October 20, 2026 Day 2 of the CHEST 2026 Annual Meeting, held October 18 to 21 in Phoenix, Arizona, brought sessions spanning pulmonary vascular disease, fibrotic interstitial lung disease (ILD), and pulmonary rehabilitation access. Highlights included a review of 3 recent randomized PE trials pointing toward catheter-based intervention in sicker intermediate-risk patients, a practical session on integrating echocardiography with right heart catheterization in pulmonary hypertension, a registry analysis linking short telomeres to Usual Interstitial Pneumonia (UIP) patterning rather than fibrosis burden in ILD, and a debate-based look at new Medicare coverage enabling virtual pulmonary rehabilitation delivery. Related to this article
This article is an excerpt. To read the full content, visit the original source. HCPLive
Related articles
CHEST 2026: Day 1 Recap — 5 Headlines to Know - HCPLive
News|Articles|October 19, 2026 Check out highlights from news published on day 1 of CHEST 2026, spanning asthma, COPD, bronchiectasis, pulmonary rehabilitation, and fibrotic ILD. Related to this articleOctober 13th, 2026Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews. Read moreOctober 18th, 2026In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL. Read moreOctober 18th, 2026Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients. Read moreOctober 16th, 2026George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD. Read moreOctober 16th, 2026Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
Innovative magnetic anastomosis enables immediate liver transplantation without cold preservation - Nature
Hang Liu1, Peng Liu3, Jiawei Yu1, Qiang Lu2, Yerong Qian1, Junxi Xiang1, Aihua Shi4, Shasha Wei4, Yi Lv1,3,4 & … Lifei Yang3,4 We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Early Intervention in Cystic Fibrosis: Limiting Multisystem Disease Progression - EMJ
The publication of this infographic was funded by Vertex Pharmaceuticals. Medical writing assistance was provided by Bethany Cooper, Ownership Health Limited, UK. Advances in cystic fibrosis care have transformed expectations for many people living with the disease. Evidence continues to support intervening early to prevent irreversible organ damage and optimise outcomes.
Changing the COPD Narrative: Interview with David Mannino - EMJ
David Mannino | Professor, University of Kentucky College of Medicine, Lexington, USA; Chief Medical Officer, COPD Foundation Could you tell us what first drew you to respiratory medicine and COPD, and how this interest has developed throughout your career?
0 comments
No comments yet. Be the first to share your thoughts!